Ignite Creation Date:
2024-05-06 @ 7:39 PM
Last Modification Date:
2024-10-26 @ 3:11 PM
Study NCT ID:
NCT06088771
Status:
RECRUITING
Last Update Posted:
2024-03-15
First Post:
2023-10-06
Brief Title:
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
Sponsor:
Icahn School of Medicine at Mount Sinai
Organization:
Icahn School of Medicine at Mount Sinai
Organization Data
Organization:
Icahn School of Medicine at Mount Sinai
Class:
OTHER
Study ID:
STUDY-23-00901
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Icahn School of Medicine at Mount Sinai
Lead Sponsor Class:
OTHER
Responsible Party:
Thomas Marron
Responsible Party Title:
Associate Professor of Medicine
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
Icahn School of Medicine at Mount Sinai
Old Name:
None
Old Organization:
None